Multiple Sclerosis

Biogen has pioneered the development of multiple sclerosis (MS) treatments for more than 25 years. We continue to innovate to advance MS treatment and improve outcomes for patients. Our research is focused on potentially transformative therapies, including the potential repair of the damage caused by MS. Our ongoing research into neurodegeneration and nerve repair will help pioneer new therapeutic solutions that may bring us closer to a cure for MS.

At the same time, we are working with leading academic institutions and MS treatment centers to advance better ways to diagnose, monitor and manage MS. We are also driving advances toward precision medicine by using new technologies to develop innovative programs and tools to better understand, measure and manage the treatment of MS. Together with our partners, we are working to enable doctors and patients to make more evidence-based, individualized treatment decisions with the goal of improving MS care.

Our innovative research collaborations merge technologies like biomarkers and wearable sensors with real-world data from routine care to generate standardized, high-quality data that may help drive personalized treatment.

We developed one of the world’s largest MS databases to investigate critical questions about this disease, including if there are potential predictors of MS progression, or if certain treatments used early enough may have potential long-term benefits for patients, such as delaying the need for walking aids and wheelchairs or slowing the deterioration of other critical functions. 

The work we are doing today in MS is designed to expand our focus well-beyond treatment and is vital to helping us better understand this disease.

For more information on multiple sclerosis, please visit www.biogencareforms.ca

 

Therapies

Today, our industry-leading portfolio of medicines helps address the diverse needs people living with MS may have throughout their lives.

We have the most robust portfolio of MS therapies in the industry with four disease-modifying therapies and one symptomatic therapy; globally, more than one in three MS patients is currently treated with a Biogen product.

Learn more about our MS therapies available in Canada.

 

Support Program for People with Multiple Sclerosis (MS)

At Biogen, we understand the complexity of available therapies for those diagnosed with MS. We are committed to continuing to improve access to our products for patients who need them.

For each therapy, we offer a a variety of patient support services: from navigating reimbursement and ongoing monitoring to disease education and nursing support. With the Biogen ONE® Support Program, all those needs are addressed, regardless of the Biogen therapy prescribed. The goal is straightforward: simplifying the MS treatment experience.

Biogen ONE® Regional Support Nurses (RSNs) are familiar with the challenges that many people face, as well as how to support them through their MS journey. They are knowledgeable about MS and Biogen therapies and uniquely equipped to understand the needs of those enrolled. Working in collaboration with an individual’s neurologist to customize services, RSNs serve as the primary contact to Biogen ONE®.
Working closely with neurologists and MS clinics, their key function is overseeing the coordination of all services required for patients to start and stay on a therapy (including reimbursement support). As members of Biogen ONE®, individuals will be given the RSN’s direct contact information to establish both a relationship and touch-point within the program.

The Biogen ONE® Support Program can help determine insurance eligibility, facilitate insurance authorizations and explore options for additional reimbursement support as necessary. For those who qualify, Biogen ONE® will provide free medication to get treatment underway while working through the reimbursement process.

In tandem with an RSN, a reimbursement specialist may contact members to:

  • Review the details of a given insurance plan and the coverage provided for prescription drugs
  • Call the insurance company to determine if any documentation is required for reimbursement of the prescribed medication
  • Assist members and their physicians with the completion of all the necessary documentation and forward it to the insurance company for processing and outcome follow-up

To access these and other services, please contact us:

Biogen ONE® Support Program
7am - 11pm ET, Monday to Friday
Tel.: 1 855 676 6300